Chemomab Therapeutics (CMMB) Price Target Raised to $25 on Positive...
Key Takeaways Chemomab Therapeutics (NASDAQ: CMMB) received a significant analyst price target upgrade from $10 to $25, while maintaining an ‘outperform’ rating. Nebokitug, the company’s lead candidate, showed positive Phase...